Complementary Challenge: Apellis Throws Down the Gauntlet

With its first FDA approval in hand for a complement inhibitor designed to treat paroxysmal nocturnal hemoglobinuria (PNH), Apellis Pharmaceuticals has thrown down the gauntlet this week by launching its commercial challenge to longtime PNH leader Alexion Pharmaceuticals, whose two blockbusters dominate the space . . .

The post Complementary Challenge: Apellis Throws Down the Gauntlet appeared first on GEN – Genetic Engineering and Biotechnology News.

Source